Flatwing fails to shift attorney fees to Pfizer unit, Anacor
29-06-2021
Bill Perry / Shutterstock.com
Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin (tavaborole), an antifungal treatment for nails.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, Kerydin, tavaborole, antifungal, fingernails, inter partes review, prior art, obvious, patents
